Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00379639 · ClinicalTrials.gov registry record · Phase 1

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

A Phase 1 study of Pancreatic Cancer, sponsored by Celgene.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT00379639 is a Phase 1 study of Pancreatic Cancer that has completed, run by Celgene. The registered enrollment target is 36 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00379639, a Phase 1 study of Pancreatic Cancer, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

This was a phase I dose escalation trial designed to determine the maximum tolerated dose (MTD) for the combination of romidepsin (depsipeptide) and gemcitabine. The study was originally planned as a Phase I/II; however only Phase I of the study was conducted.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Gemcitabine
  • DRUG Romidepsin

Study Locations (1)

Tennessee

  • Sarah Cannon Research Institute - Nashville

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2006-07-01
Est. Completion 2008-07-01
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00379639

The ClinicalTrials.gov registry entry for NCT00379639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.

NCT00379639 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00379639 about?

NCT00379639 is a clinical study titled "A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors". This was a phase I dose escalation trial designed to determine the maximum tolerated dose (MTD) for the combination of romidepsin (depsipeptide) and gemcitabine. The study was originally planned as a Phase I/II; however only Phase I of the study was conducted.

What is the current status of trial NCT00379639?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2006-07-01. Estimated completion is 2008-07-01.

What conditions does trial NCT00379639 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT00379639?

The interventions under investigation include: Gemcitabine (DRUG), Romidepsin (DRUG).

Who is sponsoring clinical trial NCT00379639?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00379639 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.